164 related articles for article (PubMed ID: 37759881)
1. Effect of Different Timing of Local Brain Radiotherapy on Survival of EGFR-Mutated NSCLC Patients with Limited Brain Metastases.
Wang Y; Wu S; Li J; Liang X; Zhou X
Brain Sci; 2023 Sep; 13(9):. PubMed ID: 37759881
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
Chen Y; Wei J; Cai J; Liu A
BMC Cancer; 2019 Aug; 19(1):793. PubMed ID: 31399067
[TBL] [Abstract][Full Text] [Related]
3. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
[TBL] [Abstract][Full Text] [Related]
4. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.
Gu Y; Xu Y; Zhuang H; Jiang W; Zhang H; Li X; Liu Y; Ma L; Zhao D; Cheng Y; Yu Y; Liu P; Qin J; Chen X; Gao J; Wang M; Liang L; Cao B
Thorac Cancer; 2021 Dec; 12(23):3157-3168. PubMed ID: 34651449
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of upfront craniocerebral radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors in patients with epidermal growth factor receptor-positive non-small cell lung cancer with brain metastases.
Zhou J; Zhou Y; Sun Y; Xiao L; Lu H; Yin X; Fan K
Front Oncol; 2023; 13():1259880. PubMed ID: 38313214
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis.
Wang W; Song Z; Zhang Y
Arch Med Sci; 2018 Oct; 14(6):1298-1307. PubMed ID: 30393484
[TBL] [Abstract][Full Text] [Related]
7. Upfront Cranial Radiotherapy vs. EGFR Tyrosine Kinase Inhibitors Alone for the Treatment of Brain Metastases From Non-small-cell Lung Cancer: A Meta-Analysis of 1465 Patients.
Du XJ; Pan SM; Lai SZ; Xu XN; Deng ML; Wang XH; Yao DC; Wu SX
Front Oncol; 2018; 8():603. PubMed ID: 30619745
[No Abstract] [Full Text] [Related]
8. EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases.
Dong K; Liang W; Zhao S; Guo M; He Q; Li C; Song H; He J; Xia X
Transl Lung Cancer Res; 2019 Jun; 8(3):268-279. PubMed ID: 31367540
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the efficacy of upfront brain radiotherapy versus deferred radiotherapy for EGFR/ALK-positive non-small cell lung cancer with brain metastases: a retrospective study.
Qian J; He Z; Wu Y; Li H; Zhang Q; Li X
BMC Cancer; 2024 Jan; 24(1):117. PubMed ID: 38262977
[TBL] [Abstract][Full Text] [Related]
10. Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer With Brain Metastases.
Yu F; Ni J; Zeng W; Zhou Y; Guo T; Zeng Y; Zhao Y; Li S; Li Y; Yang X; Zou L; Wang S; Liu Q; Li Y; Chu L; Chu X; Ye L; Yu W; Zhu Z
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):804-815. PubMed ID: 34058255
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases.
Saida Y; Watanabe S; Abe T; Shoji S; Nozaki K; Ichikawa K; Kondo R; Koyama K; Miura S; Tanaka H; Okajima M; Terada M; Ishida T; Tsukada H; Makino M; Iwashima A; Sato K; Matsumoto N; Yoshizawa H; Kikuchi T
Thorac Cancer; 2019 Nov; 10(11):2106-2116. PubMed ID: 31507098
[TBL] [Abstract][Full Text] [Related]
12. Optimal timing of hypofractionated stereotactic radiotherapy for epidermal growth factor receptor-mutated non-small-cell lung cancer patients with brain metastases.
Liang S; Liu X; Liu J; Na F; Lai J; Du L; Gong Y; Zhu J; Huang M; Zhou X; Xu Y; Zhou L
Asia Pac J Clin Oncol; 2023 Dec; 19(6):731-738. PubMed ID: 37088960
[TBL] [Abstract][Full Text] [Related]
13. Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses.
Kuan AS; Chiang CL; Wu HM; Yang HC; Chen CJ; Lin CJ; Guo WY; Pan DH; Chung WY; Lee CC
J Neurooncol; 2023 Sep; 164(3):729-739. PubMed ID: 37721662
[TBL] [Abstract][Full Text] [Related]
14. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
[TBL] [Abstract][Full Text] [Related]
15. Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer.
Wang H; Yu X; Fan Y; Jiang Y
Onco Targets Ther; 2018; 11():2149-2155. PubMed ID: 29713183
[TBL] [Abstract][Full Text] [Related]
16. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced
He ZY; Li MF; Lin JH; Lin D; Lin RJ
Cancer Manag Res; 2019; 11():2129-2138. PubMed ID: 30936745
[TBL] [Abstract][Full Text] [Related]
17. Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
Hyun DG; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
PLoS One; 2020; 15(4):e0231546. PubMed ID: 32298306
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases.
Wang C; Lu X; Zhou Z; Wang J; Hui Z; Liang J; Feng Q; Chen D; Xiao Z; Lv J; Wang X; Wang X; Zhang T; Deng L; Wang W; Xiao J; Li J; Bi N; Wang L
J Cancer; 2019; 10(9):1985-1990. PubMed ID: 31205558
[No Abstract] [Full Text] [Related]
19. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
Miyawaki E; Kenmotsu H; Mori K; Harada H; Mitsuya K; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Endo M; Nakasu Y; Gon Y; Takahashi T
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):604-613. PubMed ID: 30851347
[TBL] [Abstract][Full Text] [Related]
20. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis.
Zhao Y; Li S; Yang X; Chu L; Wang S; Tong T; Chu X; Yu F; Zeng Y; Guo T; Zhou Y; Zou L; Li Y; Ni J; Zhu Z
Int J Cancer; 2022 Apr; 150(8):1318-1328. PubMed ID: 34914096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
